🇮🇳IN
Sign In
AC

ACCPL

NSE

ACCRETION PHARMA LIMITED

₹182.10

-7.20(-3.80%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

ACCPL financial summary

For Mar 2026, ACCRETION PHARMA LIMITED reported revenue of ₹90 crore, which grew 56.2% from the previous year. Net profit was ₹10 crore, which grew 42.4% year on year, on an operating margin of 17%. Earnings per share came in at ₹8.7. Annual results are available for 3 financial years, from Mar 2024 to Mar 2026.

Revenue₹90 crore
Net profit₹10 crore
Operating margin17%
EPS₹8.7

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer